Three Infographics to Show You How to Overcome Challenges in Transitioning to Biologics Bioanalysis

Jul 8, 2016 | Biopharma, Blogs | 0 comments

The move to large molecules in Pharma is accelerating, offering unprecedented opportunities to improve human health and expand into new markets. But for those with extensive experience with small molecule bioanalysis, the shift to biologics can be challenging, from Sample Prep to Instrumentation and Software, to Methods and Training:

  • Sample Prep is complex
    • Every new biologic requires a specific sample prep strategy: sourcing reagents and researching protocols
    • Bioanalysis studies have large sample numbers
    • Tedious manual steps for enrichment, digestion, and clean-up can result in high variability
  • Instrumentation and Software have to be up to the task
    • Efficient MRM optimization is required for chromatography, multiple charge states, declustering potential and collision energy
    • Maximal sensitivity is needed for low abundance samples
    • Enhanced selectivity is important to overcome matrix interference
    • Simple software for complex data is essential, which can handle large sample sets and batches
  • Methods and Training are needed to get running quickly
    • You have to develop your sample prep protocol, source reagents and optimize your LC-MS methods, which can take months
    • You have to train your scientists to understand and run the new methods: how are you going to do it?

The challenges seem daunting, but SCIEX can help you overcome them with relative ease.  Download a three-part infographic that addresses all three challenges and describes the solutions with links to useful reference material.  The SCIEX BioBA Solution will get you up and running quickly and painlessly.Download Infographic >

Why SCIEX partners with experts around the world

Innovation in mass spectrometry does not happen in isolation. Some of the most impactful scientific advances emerge from highly specialized research communities – proteomics experts developing new peptide identification workflows, metabolomics researchers curating spectral databases, toxicologists building compound libraries, and biopharma scientists creating novel characterization methods.

Managing ADC characterization: The challenge of turning complexity into confidence

Unlike traditional monoclonal antibodies, ADCs combine an antibody backbone with linker chemistry and a cytotoxic payload. This multi-component architecture introduces overlapping layers of heterogeneity, including drug-to-antibody ratio (DAR) distributions, charge variants, post-translational modifications, and structural changes at both the intact and subunit levels. Across ADC development, these characteristics are considered critical quality attributes that must be characterized, understood, and monitored.

3 reasons ZT Scan DIA is changing the game in metabolomics

For years, metabolomics researchers have faced a frustrating reality: modern high-resolution mass spectrometers can detect tens of thousands of molecular features, yet only a fraction can be confidently identified. The challenge is no longer finding molecules. It is generating the high-quality MS/MS data needed to confidently assign structures and extract meaningful biological insights.

Posted by

0 Comments

Submit a Comment

Pin It on Pinterest

Share This

Share this post with your network